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Abstract
Cardiac amyloidosis (CA), which used to be considered a rare disease, is now increasingly recognised due to increased 
clinical awareness and the availability of advanced diagnostic techniques. CA can occur unexpectedly frequently in 
particular patient populations: among patients with heart failure with preserved left ventricular ejection fraction, as 
a phenocopy of hypertrophic cardiomyopathy, and among older patients with severe aortic stenosis. The deposition of 
abnormally folded, insoluble proteins in the extracellular matrix of tissues and organs plays a key role in the pathoge-
nesis of amyloidosis. Despite the large number of pathogenic molecules, two types account for more than 95% of CA 
cases: immunoglobulin light chain amyloidosis (AL) and transthyretin amyloidosis (ATTR). A recent paradigm shift in 
the diagnosis of CA, without the need for performing endomyocardial biopsy, has occurred as a result of technological 
advances in imaging and the development of new scintigraphy protocols. A combination of positive scintigraphic exami-
nation performed with bone-avid tracers and the absence of detectable monoclonal protein in serum or urine justifies 
a non-invasive diagnosis of ATTR. Early identification of affected patients remains crucial in order to improve prognosis, 
especially in patients with AL, in whom progression of the disease from the moment of heart involvement is extremely 
swift without causal treatment. There has recently been an exponential development of novel agents designed for 
patients with cardiomyopathy in the course of ATTR, which as a result, hopefully, in the future could become a curable 
disease. In the following article we present recent advances in the diagnosis and treatment of CA.
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Introduction
In the past, cardiac amyloidosis was considered a rare 
disease; nowadays, however, owing to increased clinical 
awareness and the availability of advanced diagnostic 
methods, it is being diagnosed more and more frequently. 
The deposition of misfolded, insoluble proteins in extra-
cellular matrix of various tissues and organs is the key 
element in the pathogenesis of amyloidosis. Currently, over 
30 different precursor proteins, native or mutated, that 
have the potential to form amyloid fibrils, are known; by 
accumulating in tissues, they can lead to the development 
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Currently, there is no reliable epidemiological data con-
cerning ATTR occurrence in Poland, and published reports 
are limited to a small number of cases [19].
Current diagnostic procedure  
for cardiac amyloidosis
Electrocardiography
Patients with cardiomyopathy in the course of amyloidosis 
may develop characteristic electrocardiogram (ECG) chan-
ges as the disease progresses. There is low QRS complex 
voltage — below 0.5 mV in limb leads and below 1.0 mV in 
precordial leads. ST-T segment changes similar to those 
which occur in the course of myocardial ischaemia — 
a pseudoinfarction pattern with no significant narrowing of 
coronary arteries — are typical. Unexplained hypertrophy of 
the left ventricular muscle identified via echocardiography 
coupled with simultaneous low QRS complex voltage in 
ECG is a characteristic feature of amyloid cardiomyopathy. 
Although the above cardiographic phenomena are treated 
as red diagnostic flags, they are not sufficiently sensitive 
to provide a definitive confirmation of diagnosis [21]. Fur-
thermore, due to fibrosis of atrial walls and the electrical 
conduction system, conduction disorders and relatively 
frequent (7–25%) development of atrial flutter and fibril-
lation, are observed [21].
Echocardiography
Echocardiographic examination plays a very important 
role in CA diagnosis. At the early stages of the disease, the 
examination reveals progressive left ventricular diastolic 
dysfunction; systolic function is also severely reduced at 
very advanced stages of the disease. Classic CA phenotype 
corresponds to restrictive cardiomyopathy and is characte-
rised by increased thickness of the left ventricular muscle, 
non-enlarged left ventricular chamber, dilated atria and 
features of elevated filling pressure. Left ventricular ejec-
tion fraction (LVEF) decreases as the disease progresses, 
which means that HFpEF can also progress into a much 
more severe heart failure form with reduced LVEF (HFrEF). 
Other features of CA include left ventricular hypertrophy, 
pericardial effusion, thickening of the interatrial septum, 
thickening of the heart valves, and intracardiac thrombi [17].
Owing to the development of advanced technology 
in the field of echocardiography, longitudinal strain as-
sessment has become the standard tool for assessing 
myocardial deformation, which was initially assessed via 
magnetic resonance imaging (MRI) of the heart. Speckle 
tracking enables assessment of both global longitudinal 
strain (GLS) and segmental longitudinal strain (SLS), with 
relative left ventricular apical sparing of longitudinal strain 
considered to be a defining characteristic of CA (Figure 1). 
Relative apical longitudinal strain index makes it possible 
of systemic amyloidosis [1–3]. Despite such a high number 
of pathogenic proteins, two types are responsible for over 
95% of cases of cardiac amyloidosis (CA): immunoglobulin 
light-chain (AL) amyloidosis and transthyretin amyloidosis 
(ATTR) [4]. Other, very uncommon, amyloid types that can 
lead to CA are amyloid A, apolipoprotein AI, heavy chain and 
atrial natriuretic peptide (ANP). On the one hand, accumu-
lation of amyloid in the heart causes calcium metabolism 
disorders, which leads to dysfunction of mitochondria and 
cell membrane, activation of oxygen free radicals and, ulti-
mately, cell death [3, 4]. On the other hand, amyloid fibrils 
accumulating in the extracellular space of the myocardium 
cause progressive diastolic dysfunction, and, in more ad-
vanced stages, systolic dysfunction too. This leads to the 
development of hypertrophic or restrictive cardiomyopathy 
phenotype [5–8].
Epidemiology and clinical presentation
The incidence of AL, the most common subtype of systemic 
amyloidosis (70–80%), is approx. 1–1.5 cases/100,000 
persons per year [9]. The disease is most often seen in 
men aged over 65 [10]. Monoclonal free light chains (FLCs) 
type lambda or kappa, produced by pathological plasma 
cell growth in the bone marrow, are the precursor protein 
[11]. AL is more aggressive than ATTR; median survival of 
untreated patients who present symptoms of cardiomyo-
pathy is less than six months. Early identification of such 
patients is thus crucial for prolongation of life [12].
Transthyretin (TTR), also known as prealbumin, physio-
logically synthesised in the liver, is a transport protein for 
thyroxine and retinol. Misfolding of TTR leads to amyloi-
dogenesis. There are two distinct forms of ATTR: acquired 
wild-type ATTR (ATTRwt), also known as senile amyloidosis, 
and hereditary ATTR (ATTRm).
Recently published findings have shown that the dise-
ase may occur more frequently in specific patient popu-
lations: in 13% of ones with heart failure with preserved 
left ventricular ejection fraction (HFpEF), in 5% of cases of 
hypertrophic cardiomyopathy (HCM), and in 16% of patients 
with severe aortic stenosis qualified for transcatheter aortic 
valve implantation (TAVI) [13–15]. ATTRwt typically affects 
older men with heart failure, and is often comorbid with 
carpal tunnel syndrome and lumbar spinal stenosis [16]. 
The inherited in an autosomally dominant manner ATTRm 
form develops as a result of TTR gene mutation. Currently, 
over 120 pathogenic TTR variants are known; as they ex-
hibit ethnic and geographical variability, the clinical picture 
and prognosis of the disease vary. ATTRm patients present 
symptoms of cardiomyopathy at the age of approx. 30–50, 
depending on the type of mutation, and the clinical picture 
can frequently include sensorimotor polyneuropathy [17]. 
Average survival from the date of diagnosis is 2–6 years [18].
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to differentiate CA from other causes of left ventricular 
hypertrophy (with 93% sensitivity and 82% specificity) [22].
Magnetic resonance imaging
MRI is a useful diagnostic tool for patients with suspected 
CA. Typically, beyond morphological features of the heart, 
diffuse, subendocardial late gadolinium enhancement 
(LGE) is observed after administration of a contrast agent. 
Occurrence of this image is characterised by excellent sen-
sitivity of 93% for CA, but it fails to differentiate between 
different types of the amyloid itself [23].
Radioisotope diagnostics  
— a new diagnostic algorithm
Single-photon emission computed tomography (SPECT) 
has become a key technique for identifying ATTR patients. 
It utilises technetium-99m radioisotope and markers 
traditionally used for examining bones: 3,3-disphono-1,2-
-propanodicarboxylic acid (DPD), methylenediphosphonic 
acid (MDP), and pyrophosphate (PYP). It should be noted 
that the procedure is carried out on the basis of various 
bone imaging protocols, using various diagnostic criteria, 
which may hinder direct comparisons of results of research 
conducted thus far [24–27].
The use of this non-invasive method for differentiating 
AL and ATTR cardiac amyloidosis was validated by Perugini 
et al. [24]. Moreover, the authors also introduced a four-
-point scale based on assessment of marker uptake in the 
bones, heart and soft tissue (Figure 2), which is still used 
today [24]. During the study, which involved 1,217 patients 
and included both SPECT with 99mTc-PYP and with 99mTc-
-DPD, a negative result excluded TTR amyloidosis with a pro-
bability of 99%. A positive image had a specificity of 86%, 
which was caused by a slight marker uptake in patients 
with the AL form [28]. Combining a positive bone scintigram 
result with the absence of monoclonal protein in blood or 
urine was proposed; this caused specificity to increase to 
100% [24]. Similarly, SPECT with PYP has a sensitivity and 
specificity of 88% in detecting ATTR cardiac amyloidosis; 
following introduction of heart-to-contralateral ratio, with 
Figure 1. Echocardiographic features of cardiac amyloidosis; A. Speckle-tracking, visible preserved apical segmental strain and reduced 
basal segmental strain — apical sparing; B. Four-chamber apical view, visible classic features of cardiac amyloidosis — non-enlarged left 
ventricle, enlarged atria, thickening of left ventricular muscle, granular echostructure of muscle. C. Tissue Doppler echocardiography — slow 
early diastolic speed of septal part of mitral annulus; D. Flow through mitral valve recorded using pulsed-wave Doppler imaging — grade 3 
left ventricular diastolic dysfunction
A B
C D
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a cut-off point of > 1.6, sensitivity increased to 91%, and 
specificity to 92% [29]. Currently, it is known that marker 
uptake in SPECT correlates with the left ventricular muscle 
hypertrophy observed in echocardiographic examination; 
however, scintigraphic changes can be observed at earlier 
stages of the disease, when the thickness of the muscle 
is not greater than the cut-off point of 12 mm [30]. Deve-
lopment of this imaging technique lead to introduction of 
a non-invasive diagnostic approach of the unexplained left 
ventricular muscle hypertrophy in larger populations — in 
a study involving 12,521 patients who underwent bone 
SPECT, the prevalence of cardiac amyloidosis was estima-
ted to be 0.36% [31].
A recent paradigm shift in CA diagnosis is the result of 
technological advances in imaging. Positive bone SPECT 
imaging, specifically a marker uptake score of 2 or 3, with 
no detectable monoclonal protein in the serum or in the 
urine, enables a non-invasive diagnosis of ATTR (Figure 3) 
[28]. Conventional histopathology and amyloid type deter-
mination are still necessary in cases which do not meet 
these diagnostic criteria.
Histology
Abdominal fat biopsy is a procedure which directly con-
firms the presence of amyloid; less frequently, biopsies are 
taken from other sites, mainly in cases where symptoms 
of involvement of these organs also occur. Low sensitivity 
of abdominal fat aspiration, respectively 84% for AL, 15% 
for ATTRwt, and 45% for ATTRm, can delay diagnosis [32]. 
To confirm deposition of amyloid in the myocardium, a right 
ventricular biopsy is performed; currently, due to the in-
troduction of the non-invasive diagnostic algorithm, this 
procedure is carried out less and less frequently.
During histopathological examination, deposits of 
amyloid are detected with Congo red staining. In polarised 
light, amyloid presents apple-green (birefringence). Further 
amyloid type determination may be performed on the basis 
of analysis of the structure of amyloid deposits using im-
munohistochemistry, mass spectrometry or immune elec-
tron microscopy. This is important for diagnosing the type 
of amyloidosis and, consequently, choosing appropriate 
therapy. It should be noted, however, that the availability 
of amyloid typing techniques is limited to few highly-spe-
cialized pathomorphological laboratories, thus they are 
performed relatively rarely in clinical practice in Poland.
Therapy in cardiac amyloidosis
Treatment of cardiovascular complications 
Both interstitial amyloid accumulation and subendocardial 
fibrosis secondary to ischaemia lead to morphological and 
functional changes in the heart. Amyloid infiltration leads 
to simultaneous thickening of walls, with normal or even 
reduced volume of the left ventricle, and consequently 
to the development of severe diastolic dysfunction. Atrial 
dysfunction can also lead to diastolic ventricular filling 
disorders. The above pathological changes cause reduced 
ejection fraction with significantly elevated intracardiac 
pressure [17].
Most drugs used in HFrEF may be harmful due to the 
unique pathology of amyloidosis. Angiotensin-conver ting- 
-enzyme inhibitors (ACE-Is) and angiotensin II receptor 
blockers (ARBs) entail a risk of severe hypotension caused 
by activation of the renin-angiotensin-aldosterone axis 
due to autonomic dysfunction. Beta-blockers can also 
be harmful, as they reduce cardiac output secondary to 
heart rate reduction and negative inotropic effect. Calcium 
channel blockers, as well as digitalis, should be avoided, 
as they bind irreversibly to amyloid fibrils and can cause 
severe side effects [33, 34]. Diuretics remain a first-line 
drug. A combination of loop diuretics and mineralocorticoid 
receptor antagonists has shown efficacy [17]. During the 
course of atrial fibrillation, which affects a large proportion 
of CA patients, rhythm control is very important. Calcium 
Figure 2. This figure presents a planar scintigraphic examination 
following administration of a Tc-99m-DPD tracer. Study shows 
increased radiotracer cardiac accumulation, specifically in grade 
3 with strong uptake in cardiac region and decreased or absent 
bone signal. This scan is consistent with ATTR cardiac amyloidosis, 
in this case caused by TTR mutation
A B
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channel blockers and beta-blockers should be avoided, 
while on the other hand, amiodarone shows the highest 
safety of use [17].
Treatment of light-chain amyloidosis
The goal of AL amyloidosis treatment is to eliminate the 
clonal plasma cells which produce the immunoglobulin light 
chain [35]. Classification of patients into risk groups before 
commencing treatment is of the utmost importance; this 
is usually done in accordance with the Mayo Clinic scale, 
which takes into account cardiac enzyme concentrations 
and the difference between serum concentrations of kappa 
and lambda FLCs [36]. In the low-risk group, for younger 
patients, experts recommend therapy using large doses 
of melphalan, supported by bone marrow autologous hae-
matopoietic stem cell transplantation with possible consoli-
dation therapy using bortezomib. For the most numerous 
(70% of patients) mid-risk group, chemotherapy using mel-
phalan and dexamethasone as well as bortezomib-based 
regimens are the standard for haematological treatment. 
Finally, for the high-risk group, reduced-intensity chemo-
therapy is recommended. In treatment of recurrent and 
resistant forms of AL amyloidosis, therapeutic regimens are 
based on immunomodulatory drugs, as well as new genera-
tion proteasome inhibitors, bendamustine and monoclonal 
antibodies [35]. In specific cases, AL amyloidosis patients 
can undergo organ transplantations, such as kidney and 
heart transplantations [35].
Treatment of transthyretin amyloidosis
Organ transplantation
Great expectations were placed on liver transplantation 
as a promising strategy for ATTRm treatment, which could 
remove the source of circulating pathogenic TTR protein 
[37]. Unfortunately, it was shown that an isolated liver 
transplantation entails a very high risk of the development 
of progressive amyloid cardiomyopathy [38, 39]. For this 
reason, according to the International Society for Heart and 
Lung Transplantation, simultaneous heart and liver trans-
plantation should be considered for young ATTRm patients 
in order to prevent progression of a systemic disease. For 
older patients with dominant heart failure symptoms (wild- 
-type or Val122Ile variant), isolated heart transplantation 
should be considered [39].
Gene therapy
Patisiran is a short interfering RNA (siRNA) molecule which 
targets TTR expression. The randomised 18-month-long 
phase 3 APOLLO trial (NCT01960348), which evaluated the 
efficacy and safety of patisiran in a group of 225 patients 
with neuropathy, showed that, compared to the control 
group, ATTRm patients treated with patisiran presented 
with improved quality of life and reduced neurological 
symptoms. Moreover, in the subgroup of patients with 
cardiomyopathy, the drug reduced NTproBNP natriuretic 
peptide levels and had a positive effect on left ventricular 
Figure 3. Authors’ modification of the algorithm of non-invasive diagnosis of cardiac amyloidosis (based on [28]); HFpEF — heart failure with 
preserved ejection fraction; 99mTc-DPD — technetium-99m-3,3-diphosphono-1,2 propanodicarboxylic acid; HMDP — acidhydroxymethylene 
diphosphonate; PYP — pyrophosphate; CMR — cardiac magnetic resonance; AL — light chain amyloidosis; ATTR — transthyretin amyloidosis; 
ATTRm — ATTR mutant; ATTRwt — ATTR wild-type
Left ventricular hypertrophy, HFpEF, aortic stenosis, apical sparing
99mCardiac scintigraphy Tc-DPD/HMDP/PYP
Grade 1Grade 0 Grade 2–3
Serum light chains (κ and λ), immunofixation (serum and urine)
Yes No No Yes Yes No
Specialist assessment: 
● histological diagnosis   
● amyloid type determination 
ATTR cardiac 
amyloidosis
Reassessment via 
cardiac magnetic
resonance imaging
AL/ATTR cardiac 
amyloidosis improbable
Nie
AL/ATTR/apolipoprotein/other 
cardiac amyloidosis
ATTRm ATTRwt
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remodelling. It has to be noted, however, that the APOLLO 
trial concerned patients with neuropathic ATTRm variants, 
and the efficacy and safety of the drug in the cardiomyopa-
thy patient group is yet to be verified [40–42].
Inotersen is a TTR antisense oligonucleotide, which inhi-
bits TTR synthesis in hepatocytes. The randomised 66-week-
long phase 3 NEURO-TTR (NCT01737398) trial evaluated the 
efficacy and safety of the drug administered subcutaneously 
at a dose of 300 mg once per week in a group of 172 patients 
with familial amyloid polyneuropathy. The trial showed that 
inotersen reduces neurological symptoms and improves 
quality of life, but also that the drug has adverse effects, the 
most frequent of which were glomerulonephritis (3%) and 
life-threatening thrombocytopenia (3%) [43].
Tetramer stabilisation therapy
2018 saw the publication of results from a groundbreaking 
trial — ATTR-ACT (NCT01994889) — in which patients with 
the cardiac form of ATTR were treated using tafamidis [44]. 
Tafamidis is a benzoxazole derivative which selectively 
and strongly binds to native tetrameric TTR, preventing 
its dissociation into monomers. The trial enrolled 441 pa-
tients with amyloid cardiomyopathy in the course of ATTR, 
who were randomly assigned (2:1:2) to treatment using 
tafamidis at a dose of 80 mg, or treatment using tafamidis 
at a dose of 20 mg, or treatment using a placebo, and 
then observed for 30 months. Study reported significant 
reduction in mortality and urgent hospitalisations rates in 
the group treated with tafamidis. Furthermore, patients 
treated actively were characterised by better physical fit-
ness and enjoyed improved quality of life. The introduction 
of tafamidis into treatment provides the first real chance to 
prolong the life of patients with the cardiac form of ATTR, 
given that no other causal therapy in the course of this 
disease is available. Tafamidis is also already registered 
for the treatment of patients with symptomatic ATTR 
polyneuropathy [45].
Diflunisal is a nonsteroidal anti-inflammatory drug 
which has the ability to stabilise TTR tetramers in vitro. In 
a randomised phase 3 trial, 130 patients with ATTR with 
symptomatic polyneuropathy were randomly assigned 
to diflunisal at a dose of 500 mg/day or to a placebo, 
and then observed for two years [46]. The trial showed 
that diflunisal reduced the progression of neurological 
symptoms; however, no beneficial effect with respect to 
cardiomyopathy was identified. Although this relatively large 
dose of diflunisal was well-tolerated in this trial, its effect 
as a cyclooxygenase inhibitor can potentially lead to kidney 
and gastrointestinal tract injury, as well as fluid retention 
and difficulties in arterial pressure management. Potential 
adverse effects remain a serious therapeutic problem. 
The AG10 is a new TTR-stabilising compound. The 
AG10 drug has a similar structure of the thyroxine-binding 
site as the anti-amyloidogenic protective Thr119Met variant 
and specifically binds to the TTR tetramer, hampering its 
dissociation. An in vitro trial showed that the preparation 
caused increased tetrameric stability of TTR compared to 
tafamidis and diflunisal [47]. A randomised phase 2 trial 
(NCT03458130) confirmed the safety and efficacy of 
AG10 in patients with ATTRwt and ATTRm cardiomyopathy; 
a phase 3 trial is currently underway [48].
Amyloid degradation affecting therapy
Doxycycline and tauroursodeoxycholic acid (TUDCA) degrade 
TTR deposits; moreover, a few reports on their mitigating 
effect on ATTR progression have already been published [49, 
50]. A trial (NCT01855360) which evaluated the tolerance 
and efficacy of a combination of doxycycline (100 mg orally 
twice daily) and TUDCA (250 mg orally thrice daily) in 38 
patients with cardiomyopathy in the course of ATTRm or 
ATTRwt for a period of observation of 18 months was recent-
ly completed, but its results have not yet been published.
Epigallocatechin gallate is an organic chemical com-
pound classified as a flavonoid found in large quantities in 
green tea, which may inhibit the formation of TTR amyloid 
fibrils and disaggregate amyloid deposits [51]. Two small, 
12-month-long observation trials showed that consump-
tion of green tea reduced the mass of the left ventricle 
by 6–13%, as assessed via magnetic resonance imaging 
in ATTRwt patients [52, 53]. Antibodies which selectively 
bind to amyloid molecules, which could be utilised via 
immunotherapeutic removal of deposits from key organs, 
including the liver, in patients with systemic amyloidosis, 
are also being studied [54].
Conclusions
Both correct diagnosis and treatment of CA are challenging, 
even for multidisciplinary teams dedicated to the heart 
failure treatment. The development of new imaging tech-
niques, and as a result the change of diagnostic algorithm, 
have in recent years given rise to numerous reports stress-
ing higher prevalence of ATTR in specific patient subpopu-
lations: those with aortic stenosis, and older people with 
unexplained left ventricular hypertrophy, HCM or HFpEF. 
Early identification of patients is vital in terms of improved 
prognosis, especially with respect to AL patients, in whom 
progression of the primary disease is extremely rapid 
without causal treatment. Furthermore, novel emerging 
ATTR therapies are currently underway; in particular, the 
effects of tafamidis have been demonstrated with respect 
to improved survivability of patients with cardiomyopathy, 
which thus may have the potential to become a curable 
disease in the future.
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Streszczenie
Amyloidoza serca (CA), uważana w przeszłości za chorobę rzadką, obecnie jest coraz częściej rozpoznawana dzięki 
zwiększonej świadomości klinicznej oraz dostępnym zaawansowanym metodom diagnostycznym. Może ona występować 
zaskakująco często w szczególnych populacjach pacjentów — wśród osób z niewydolnością serca z zachowaną frakcją 
wyrzutową, jako fenokopia kardiomiopatii przerostowej oraz wśród starszych pacjentów z ciężką stenozą aortalną. 
Kluczową rolę w patogenezie amyloidozy odgrywa odkładanie się w macierzy pozakomórkowej tkanek i narządów depo-
zytów nieprawidłowo sfałdowanych, nierozpuszczalnych białek. Mimo dużej liczby patogennych cząsteczek, to dwa ich 
rodzaje odpowiadają za ponad 95% przypadków CA — amyloidozę łańcuchów lekkich immunoglobulin (AL) i amyloidozę 
transtyretynową (ATTR). Niedawna zmiana paradygmatu w diagnozowaniu CA bez konieczności wykonywania biopsji 
endomiokardialnej dokonała się wraz z postępem technologicznym w obrazowaniu i rozwoju nowych protokołów badania 
scyntygraficznego. Pozytywne obrazowanie scyntygraficzne z użyciem znaczników klasycznie stosowanych w obrazo-
waniu układu kostnego, w przypadku braku wykrywalnego białka monoklonalnego w surowicy lub moczu, pozwala na 
nieinwazyjną diagnozę ATTR. Wczesna identyfikacja chorych jest kluczowa w kontekście poprawy rokowania, zwłaszcza 
pacjentów z AL, u których postęp choroby podstawowej od czasu zajęcia serca jest dramatycznie szybki. Obserwuje się 
ogromny rozwój nowych leków przeznaczonych dla pacjentów z kardiomiopatią w przebiegu ATTR, która w przyszłości ma 
szansę stać się chorobą uleczalną. W poniższym artykule przedstawiono ostatnie postępy w diagnostyce i leczeniu CA.
Słowa kluczowe: amyloidoza, amyloidoza łańcuchów lekkich immunoglobulin, amyloidoza transtyretynowa,  
transtyretyna, kardiomiopatia, niewydolność serca
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